There are growth factor serums that look impressive on a label — and then there is Bradceuticals Gold Mesenchymal Stem Cell Growth Factor Serum, which delivers the real thing. Formulated with bone marrow-derived mesenchymal stem cell conditioned media, it contains a broad spectrum of biologically active growth factors — including epidermal growth factor — at concentrations that actually reach your skin’s repair machinery. It works beautifully as a daily serum on its own, but if you want to see what it is truly capable of, apply it immediately after microneedling. The open microchannels allow these growth factors to bypass the stratum corneum and penetrate to the dermal layer directly — and the difference in results compared to surface application alone is something you have to experience to believe.
Epidermal growth factor has become one of the most discussed actives in advanced skincare, and for good reason. Its role in tissue repair, cellular regeneration, and reversing signs of aging has been studied in clinical settings for decades. This article breaks down what the science actually says — in plain language — so you can make genuinely informed decisions about growth factor skincare.
What Is Epidermal Growth Factor?
Epidermal growth factor is a small mitogenic polypeptide — a chain of 53 amino acids — that plays a central role in regulating cell survival, proliferation, migration, and differentiation throughout the body. It was first isolated from mouse submaxillary gland tissue in the early 1960s by Stanley Cohen, work that ultimately contributed to a Nobel Prize in Physiology or Medicine.
EGF works by binding to the epidermal growth factor receptor (EGFR), a cell surface protein found in high density on keratinocytes, fibroblasts, and other epithelial cells. When EGF binds to EGFR, it triggers a cascade of intracellular signaling pathways that regulate cell division, movement, and survival. In the skin specifically, this cascade stimulates keratinocyte proliferation, fibroblast activity, and the synthesis of structural proteins including collagen and hyaluronic acid.
A comprehensive PMC review of EGF in dermatological practice confirmed that recombinant human EGF (rhEGF) plays a pivotal role in wound healing and tissue homeostasis, and that its regenerative properties have made it an active subject of clinical research for skin repair and anti-aging applications. [PMC10333026]
Your body produces epidermal growth factor naturally — it is present in saliva, tears, urine, plasma, and many tissues — but production declines meaningfully with age. This decline contributes to slower wound healing, reduced collagen synthesis, and the gradual deterioration of skin structure that characterizes aging. Supplementing through well-formulated topical products is the basis for EGF’s growing role in cosmeceutical skincare.
7 Transformative Facts About Epidermal Growth Factor
Fact 1: Epidermal Growth Factor Accelerates Wound Healing Through Measurable Biological Mechanisms
The wound healing science behind epidermal growth factor is among the most thoroughly documented in all of growth factor research. EGF stimulates keratinocytes and fibroblasts at wound sites to divide and migrate into injured tissue, accelerating the re-epithelialization process — the restoration of the skin’s protective epithelial barrier over a wound.
A PMC study evaluating topical rhEGF ointment in a rat full-thickness wound model found that when rhEGF was applied twice daily, wound closure was significantly enhanced from day 5 through day 12 compared to control. Histological analysis confirmed that rhEGF treatment increased epidermal cell proliferation and elevated both alpha-smooth muscle actin in myofibroblasts and prolyl 4-hydroxylase expression — markers of active collagen deposition and wound contraction. [PMC3242099]
A systematic review and meta-analysis of randomized controlled trials evaluating growth factor products including EGF for acute skin wounds found that wounds treated with growth factors healed an average of 3.02 days faster than those in the control group (95% CI: −3.31 to −2.74, p < 0.001). [PMC8900703]
This wound healing mechanism is directly relevant to skincare: the similarities between the biochemical pathways of skin aging and wound healing are well established in the literature. Aging skin, like a wound, suffers from impaired fibroblast function, reduced growth factor signaling, and diminished collagen synthesis. EGF addresses all three.
Fact 2: Epidermal Growth Factor Has Been Clinically Studied for Anti-Aging and Skin Rejuvenation
The aesthetic applications of recombinant human EGF have been the subject of systematic clinical research. A PMC systematic review of EGF in aesthetics and regenerative medicine analyzed 28 publications, of which 23 were clinical or preclinical trials. The review concluded that most clinical trials reported the efficacy of rhEGF in reversing signs of skin aging, including fine lines, grooves, hyperpigmentation, hydration loss, and reductions in epidermal and dermal thickness. [PMC8423211]
Specific findings from the clinical literature cited in this review include: a three-month topical EGF serum application that significantly improved brown pigmentation, skin texture, pore size, and wrinkles in 29 women with photoaged skin; and a four-week application of micro-spicule EGF cream that produced clinical improvement in periocular wrinkles in 20 Korean women. [PMC10333026]
In vitro studies confirmed that rhEGF promotes the migration and contractility of aged fibroblasts and increases both hyaluronic acid and collagen synthesis — providing the mechanistic foundation for its observed clinical effects on aging skin. [PMC10333026]
Fact 3: EGF Levels Naturally Decline With Age — and This Accelerates Skin Deterioration
One of the fundamental reasons epidermal growth factor is so relevant to anti-aging skincare is that its production declines as part of the aging process itself. Research on EGFR signaling and skin aging confirms that reduced EGF receptor expression in aged skin is directly associated with aging-associated skin changes including epidermal thinning, loss of hyaluronic acid, and increased expression of senescence markers. A PMC study examining the mechanisms of skin aging induced by EGFR inhibitors found that impaired EGFR signaling in skin produced changes strikingly similar to intrinsic aging — including reduced epidermal thickness, barrier gene downregulation, and upregulation of pro-inflammatory cytokines — supporting the conclusion that intact EGF signaling is essential to maintaining youthful skin architecture. [PMC5611667]
This parallels the logic behind growth factor serums: replenishing the bioactive signals that your skin’s cells are no longer receiving in adequate quantities from endogenous sources.
Fact 4: Epidermal Growth Factor Is Among the Most Potent Enhancers of Post-Microneedling Results
Microneedling and epidermal growth factor are a scientifically logical combination. Microneedling creates controlled micro-injuries that trigger the wound-healing cascade — the same cascade that EGF helps govern. By applying an EGF-containing serum post-microneedling, you are delivering the precise molecular signal that the wound response is actively calling for, directly through open microchannels that bypass the stratum corneum barrier.
A PMC randomized controlled trial evaluating microneedling with a human growth factor serum versus microneedling with hyaluronic acid alone found that the addition of growth factors improved skin texture and hydration to a significantly higher degree, supporting the hypothesis that growth factors downregulate post-procedure inflammation while extending collagen synthesis. [PMC7716740]
This is the foundation of the Bradceuticals Gold post-microneedling protocol: applying a concentrated source of mesenchymal stem cell-derived growth factors — including EGF — immediately post-procedure when the skin is most receptive to their regenerative signals.
Fact 5: Topical EGF Is Considered Safe When Used in Cosmetic Concentrations
Concerns about epidermal growth factor’s relationship to cancer arise from its role in EGFR signaling — a pathway that, when dysregulated through mutation, is associated with certain tumors. It is important to distinguish between normal physiological EGF signaling and pathological EGFR overexpression caused by genetic mutation. EGF does not cause receptor overexpression; cancer cells with mutant EGFR exist independently of EGF exposure.
A comprehensive PMC clinical safety review of topical EGF spanning 16 clinical reports covering its use since 1989 found no reports providing evidence linking EGF clinical use with cancer. A 15-year follow-up survey of burn patients who had received topical EGF found cancer incidence comparable to both the untreated control group and the age-matched national population average. The review concluded that EGF therapeutic efficacy and excellent tolerability are demonstrated, with a lack of long-term adverse effects highlighted in studies spanning six, twelve, and twenty-four months of follow-up. [PMC7951530]
For individuals with a current or historical cancer diagnosis, a conversation with their dermatologist before using EGF-containing skincare is always appropriate.
Fact 6: Epidermal Growth Factor Works Synergistically With Other Growth Factors
Epidermal growth factor does not operate in isolation in the skin. In the most effective growth factor formulations, EGF works alongside TGF-β (which drives collagen synthesis), VEGF (which supports vascularization and nutrient delivery), PDGF (which activates fibroblast proliferation), bFGF (which stimulates cellular repair), and HGF (which supports epithelial regeneration).
A 24-week double-blind, randomized, placebo-controlled clinical trial of a novel growth factor-based cosmeceutical published in PMC demonstrated that treatment with the growth factor formula produced significantly greater reductions in sagging, coarse wrinkles, fine wrinkles, overall photodamage, and hyperpigmentation compared to placebo. Skin biopsies confirmed increased expression of collagen Types I, III, IV, and VII, elastin, and epidermal barrier proteins. Subjects reported a median decrease in self-perceived age of six years after 12 weeks of use. [PMC9823186]
This synergistic effect is why formulations built around mesenchymal stem cell conditioned media — which contains the full physiologic spectrum of growth factors — outperform products that deliver isolated EGF alone.
Fact 7: The Most Effective Delivery Method for EGF Is Through Disrupted Skin or Intradermal Pathways
One of the recurring findings in EGF research is that intact skin presents a significant absorption barrier for the molecule. EGF is a relatively large protein, and the stratum corneum substantially limits its transdermal penetration under normal conditions.
This is precisely why post-microneedling application is the gold standard for topical EGF delivery. When microneedles create temporary microchannels through the stratum corneum, EGF and other growth factors gain direct access to the dermis — the layer where fibroblasts, the target cells for collagen production, are located. Published PMC research on microneedle-mediated transdermal delivery confirms that microchannels created by needling substantially enhance the intradermal delivery of macromolecules, including proteins of the size and molecular weight of growth factors. [PMC7931162]
The systematic review of EGF in aesthetics noted that EGF is more effectively applied by intradermal routes or transdermal patches, and that these delivery methods result in greater reduction of fine lines, folds, and hyperpigmentation compared to surface application alone. [PMC8423211]
How Epidermal Growth Factor Fits Into Your Skincare Routine
Understanding how to incorporate epidermal growth factor into a daily skincare routine depends on what form of delivery you are using.
For daily serum use: Apply Bradceuticals Gold to clean skin after cleansing and toning, before moisturizer. The growth factors work cumulatively — consistent daily use supports ongoing fibroblast activity and collagen maintenance. Initial improvements in hydration and skin tone are typically noticeable within two to four weeks; firming and wrinkle reduction develop over eight to twelve weeks.
For post-microneedling use: Apply Bradceuticals Gold immediately following your session while microchannels are open. Press gently into skin using clean fingertips — never rub aggressively over fresh microchannels. Follow with hyaluronic acid and a fragrance-free moisturizer. Avoid retinoids, exfoliating acids, and vitamin C for 48–72 hours post-procedure.
Layering compatibility: Epidermal growth factor serums are generally compatible with hyaluronic acid, niacinamide, and ceramide serums. They pair exceptionally well with peptide formulas, as the signaling mechanisms of peptides and growth factors are complementary. Avoid layering with high-concentration retinoids or acids in the same application step.
Epidermal Growth Factor vs. Other Growth Factors: Understanding the Differences
EGF is one of the most studied growth factors in skincare, but it functions within a larger ecosystem of signaling proteins that collectively govern skin health.
EGF (Epidermal Growth Factor): Primarily targets keratinocytes and fibroblasts to drive proliferation, migration, and differentiation. Central to wound healing, anti-aging, and post-procedure recovery.
TGF-β (Transforming Growth Factor Beta): The primary collagen synthesis driver. Activates fibroblasts to produce collagen Types I and III. Works synergistically with EGF to deliver structural rebuilding alongside cellular repair.
VEGF (Vascular Endothelial Growth Factor): Stimulates new blood vessel formation, improving nutrient and oxygen delivery to the dermis. Supports the healing microenvironment that EGF requires to function optimally.
PDGF (Platelet-Derived Growth Factor): Activates fibroblast proliferation and extracellular matrix remodeling. Plays a key role in the early wound healing cascade that microneedling initiates.
bFGF (Basic Fibroblast Growth Factor): Stimulates fibroblast proliferation and is involved in angiogenesis and tissue repair. Works alongside EGF in the wound healing response.
The most clinically effective growth factor serums — including those built on mesenchymal stem cell conditioned media — contain all of these signals in physiologically balanced proportions, rather than relying on any single growth factor in isolation.
Frequently Asked Questions About Epidermal Growth Factor
Is epidermal growth factor safe for daily use in skincare? Yes, based on the available clinical evidence. The comprehensive PMC safety review found no evidence linking topical EGF use with cancer across clinical studies spanning up to 24 months of follow-up. [PMC7951530] As with any active ingredient, individuals with cancer diagnoses should consult their dermatologist.
How quickly does topical EGF show results? Clinical studies report initial improvements in skin hydration, texture, and tone within two to four weeks of consistent daily use. Anti-aging effects — wrinkle reduction, improved firmness, fade of pigmentation — typically become measurable after eight to twelve weeks.
Can I use epidermal growth factor serum with retinoids? These actives are best separated by application time. Use your growth factor serum in the morning and retinoids at night. They target complementary mechanisms — EGF for repair and regeneration, retinoids for collagen stimulation and cellular turnover — and their effects are additive when timed correctly.
What is the difference between EGF and mesenchymal stem cell conditioned media? EGF is a single growth factor protein. Mesenchymal stem cell conditioned media contains the full secretome of MSCs — including EGF alongside TGF-β, VEGF, PDGF, bFGF, and hundreds of other bioactive proteins, cytokines, and extracellular vesicles. The physiologic breadth of MSC-CM provides more comprehensive skin repair signaling than any single isolated growth factor.
Does post-microneedling application of EGF serum make a measurable difference? Yes. The randomized controlled trial evidence confirms that microneedling combined with growth factor serum produces significantly better skin texture and hydration outcomes than microneedling alone. [PMC7716740] The open microchannels allow growth factors to reach the dermis directly — where fibroblasts and stem cells are located — dramatically increasing their bioavailability compared to surface application.
Is epidermal growth factor appropriate for sensitive skin? In general, yes. The PMC safety review found EGF to be well tolerated across clinical studies. For post-microneedling application, follow the standard post-procedure protocol: fragrance-free, minimal-irritant formulations only, and avoid other actives for 48–72 hours.
Will epidermal growth factor cause cancer? The current clinical evidence does not support this concern for topical use at cosmetic concentrations. The 15-year follow-up study found no elevated cancer incidence in EGF-treated patients versus controls. [PMC7951530] EGFR dysregulation in cancer is caused by genetic mutation, not by topical EGF exposure.
References
- Shin SH, et al. The use of epidermal growth factor in dermatological practice. PMC. 2023. PMC10333026. https://pmc.ncbi.nlm.nih.gov/articles/PMC10333026/
- Miller-Kobisher B, et al. Epidermal Growth Factor in Aesthetics and Regenerative Medicine: Systematic Review. PMC. 2021. PMC8423211. https://pmc.ncbi.nlm.nih.gov/articles/PMC8423211/
- Kwon YB, et al. Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat. PMC. 2006. PMC3242099. https://pmc.ncbi.nlm.nih.gov/articles/PMC3242099/
- Berlanga-Acosta J, et al. Epidermal growth factor in clinical practice — a review of its biological actions, clinical indications and safety implications. PMC. 2021. PMC7951530. https://pmc.ncbi.nlm.nih.gov/articles/PMC7951530/
- Parker L, et al. An Assessment of Microneedling with Topical Growth Factors for Facial Skin Rejuvenation: A Randomized Controlled Trial. PMC. 2020. PMC7716740. https://pmc.ncbi.nlm.nih.gov/articles/PMC7716740/
- Mehta RC, et al. Targeting Multiple Hallmarks of Skin Aging: Preclinical and Clinical Efficacy of a Novel Growth Factor-Based Skin Care Serum. PMC. 2023. PMC9823186. https://pmc.ncbi.nlm.nih.gov/articles/PMC9823186/
- Waghule T, et al. Microneedle for transdermal drug delivery: current trends and fabrication. PMC. 2021. PMC7931162. https://pmc.ncbi.nlm.nih.gov/articles/PMC7931162/
- Li W, et al. The clinical effectiveness and safety of using epidermal growth factor, fibroblast growth factor and GM-CSF as therapeutics in acute skin wound healing: a systematic review and meta-analysis. PMC. 2022. PMC8900703. https://pmc.ncbi.nlm.nih.gov/articles/PMC8900703/
- Freites-Martinez A, et al. Mechanisms of skin aging induced by EGFR inhibitors. PMC. 2017. PMC5611667. https://pmc.ncbi.nlm.nih.gov/articles/PMC5611667/
Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any skin condition or disease. Individual results will vary. Always consult a licensed dermatologist or qualified healthcare professional before beginning any new skincare regimen, particularly if you have a history of skin cancer, a current cancer diagnosis, or are undergoing medical treatment. The cancer safety discussion in this article reflects the current published clinical evidence for topical EGF at cosmetic concentrations and does not constitute medical guidance for oncology patients.
Last Reviewed: June 2025
About Bradceuticals : Thuy Myers is the founder of Bradceuticals which manufactures and distributes skin care and hair regrowth serums that use growth factors from human stem cells as the catalyst for regeneration. When she is not busy running the business and maintaining blogs, she is continuing her practice as a semiconductor engineer and occasionally teaches college engineering. In her free time, she enjoys the beach, working out at the gym and hanging out with her kiddo Brad.